Name of the Procedure:

Injection, fam-trastuzumab deruxtecan-nxki, 1 mg (HCPCS Code: J9358)

Common name(s): Enhertu Injection, Trastuzumab deruxtecan Technical/medical term: Fam-trastuzumab deruxtecan-nxki

Summary

Fam-trastuzumab deruxtecan-nxki injection is a treatment used primarily for certain types of cancer. It involves administering a specific medication via injection to target and destroy cancer cells.

Purpose

This injection is used to handle specific types of cancers, particularly HER2-positive breast cancer and other HER2-expressing tumors. The goal is to shrink the tumor, halt its growth, and relieve symptoms associated with the cancer.

Indications

• HER2-positive breast cancer that has spread or cannot be surgically removed.
• HER2-expressing gastric cancer.
• Other HER2-expressing tumors.
• Patients who have previously received treatments targeting the HER2 protein but where the cancer has progressed.

Preparation

• Patients should inform their healthcare provider about any medications they are taking.
• Blood tests may be required to assess overall health.
• Confirm no recent vaccinations.

Procedure Description

1. The healthcare provider determines the appropriate dose based on the patient’s weight.
2. An intravenous (IV) line is inserted into a vein.
3. The fam-trastuzumab deruxtecan-nxki medication is prepared and infused into the IV line.
4. The infusion is monitored over the prescribed period.
5. Post-infusion, the IV line is removed.

Duration

The injection typically takes approximately 90 minutes for the first dose and 30 minutes for subsequent doses.

Setting

This procedure is generally performed in an oncology clinic or hospital outpatient setting.

Personnel

• Oncologist or healthcare provider specializing in cancer treatment.
• Nurses trained in chemotherapy administration.

Risks and Complications

Common risks include:

• Nausea
• Fatigue
• Low blood cell counts
• Hair loss

• Diarrhea

  Rare risks and potential complications:

• Severe lung problems
• Heart problems
• Severe infusion reactions

Management involves close monitoring and supportive care.

Benefits

• Slowing or stopping tumor growth.
• Potentially shrinking tumors.
• Improvement in symptoms related to cancer within weeks.

Recovery

• Patients may experience mild side effects after the procedure.
• Specific instructions on managing side effects will be provided.
• Follow-up appointments to monitor blood counts and overall response to treatment.

Alternatives

• Other HER2-targeted therapies.
• Surgery.
• Radiation therapy.
• Traditional chemotherapy.

Each alternative has its own set of benefits and side effects, which the oncologist will discuss with the patient.

Patient Experience

• During the procedure: Patients may feel a slight discomfort at the IV site.
• Post-procedure: Possible side effects like fatigue and nausea; pain management plans and anti-nausea medications are often provided.
• Regular monitoring and support from the healthcare team ensure patients are comfortable and manage side effects effectively.

This comprehensive overview aims to inform patients about what to expect with the fam-trastuzumab deruxtecan-nxki injection, ensuring they are well-prepared and understand the potential outcomes and care involved.